To identify more effective therapies for NRAS‐mutant melanoma, we evaluated combinations of JQ‐1 with inhibitors of RAS effectors that are undergoing clinical evaluation for NRAS‐mutant melanoma patients. This evidence concerns the gene NRAS and melanoma.